ValuEngine upgraded shares of Selecta Biosciences, Inc. (NASDAQ:SELB) from a sell rating to a hold rating in a research note issued to investors on Friday, June 30th.
Several other brokerages have also weighed in on SELB. Zacks Investment Research lowered Selecta Biosciences from a hold rating to a sell rating in a research report on Saturday, April 1st. UBS AG reaffirmed a buy rating and issued a $26.00 target price on shares of Selecta Biosciences in a research report on Thursday, March 30th. Canaccord Genuity set a $25.00 price objective on Selecta Biosciences and gave the company a buy rating in a report on Saturday, May 13th. Finally, Needham & Company LLC restated a buy rating and set a $28.00 target price on shares of Selecta Biosciences in a research note on Tuesday, March 28th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $26.00.
Selecta Biosciences (NASDAQ:SELB) traded down 2.30% on Friday, reaching $16.98. 40,653 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $18.07 and a 200-day moving average of $14.84. Selecta Biosciences has a one year low of $10.26 and a one year high of $28.00.
Selecta Biosciences (NASDAQ:SELB) last announced its quarterly earnings data on Thursday, May 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.40. The firm had revenue of $0.14 million during the quarter. Selecta Biosciences had a negative return on equity of 76.21% and a negative net margin of 715.40%. On average, equities analysts expect that Selecta Biosciences will post ($3.34) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/07/30/selecta-biosciences-inc-nasdaqselb-raised-to-hold-at-valuengine-updated-updated-updated.html.
In other news, CFO David Siewers sold 6,886 shares of Selecta Biosciences stock in a transaction on Monday, June 26th. The stock was sold at an average price of $20.00, for a total value of $137,720.00. Following the completion of the sale, the chief financial officer now directly owns 36 shares of the company’s stock, valued at approximately $720. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edwin M. Kania, Jr. sold 266,795 shares of Selecta Biosciences stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $14.00, for a total value of $3,735,130.00. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 355,413 shares of company stock valued at $6,232,567 and have sold 321,819 shares valued at $4,765,494.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Hamilton Lane Advisors LLC raised its position in Selecta Biosciences by 21.8% in the second quarter. Hamilton Lane Advisors LLC now owns 91,125 shares of the company’s stock valued at $1,810,000 after buying an additional 16,292 shares in the last quarter. UBS Group AG raised its stake in shares of Selecta Biosciences by 1,215.9% in the first quarter. UBS Group AG now owns 71,361 shares of the company’s stock worth $1,022,000 after buying an additional 65,938 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Selecta Biosciences by 83.1% in the first quarter. Goldman Sachs Group Inc. now owns 31,588 shares of the company’s stock worth $452,000 after buying an additional 14,332 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in shares of Selecta Biosciences during the first quarter worth approximately $444,000. Finally, Hikari Power Ltd purchased a new stake in shares of Selecta Biosciences during the first quarter worth approximately $349,000. Hedge funds and other institutional investors own 45.60% of the company’s stock.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.